Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave s Q2 Revenues Slide 54 Percent, Dx Receipts Grow

NEW YORK, July 28 (GenomeWeb News) - Third Wave Technologies yesterday reported a sharp drop in total revenues along with a widening loss for the second quarter of 2005.


The company's revenues for the quarter were $5.8 million, down 54 percent from $12.6 million during the second quarter of 2004. Of that, $4.3 million came from clinical molecular diagnostics and $1.3 million from research revenues, compared to $3.4 million and $9.1 million, respectively, during last year's second quarter.


"While the long-anticipated decline in research revenue may cloud the company's top-line story in the short term, our second-quarter results show that the investments we have made and will continue to make in molecular diagnostic product development and distribution are beginning to pay off," said John Puisis, Third Wave's president and CEO, in a statement.


Research and development costs declined to $2 million, down from $3 million during last year's second quarter.


Third Wave's net loss for the quarter totaled $5.5 million, or $.13 per share, up from $106,000, or $0 per share, for the year-ago period.


As of June 30, Third Wave had $61.5 million in cash, cash equivalents, and short-term investments.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.